Quest Diagnostics Inc (DGX) was Reiterated by Barclays to “Equal Weight” according to the research note released today. The brokerage firm has raised the Price Target to $ 75 from a previous price target of $72 . Barclays advised their investors in a research report released on Apr 22, 2016.
Many Wall Street Analysts have commented on Quest Diagnostics Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 22, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 76 from a previous price target of $70 .Company shares were Reiterated by Mizuho on Apr 21, 2016 to “Buy”, Firm has raised the Price Target to $ 84 from a previous price target of $75 .Quest Diagnostics Inc was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016.
On the company’s financial health, Quest Diagnostics Inc reported $1.12 EPS for the quarter, based on the information available during the earnings call on Apr 21, 2016. Analyst had a consensus estimate of $1.12. The company had revenue of $1863.00 million for the quarter, compared to analysts expectations of $1823.36 million. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.05 EPS.
Quest Diagnostics Inc opened for trading at $74.93 and hit $75.8 on the upside on Wednesday, eventually ending the session at $75, with a gain of 0.37% or 0.28 points. The heightened volatility saw the trading volume jump to 12,03,234 shares. Company has a market cap of $10,707 M.
In a different news, on Mar 3, 2016, Michael E Prevoznik (SVP & General Counsel) sold 3,815 shares at $68.40 per share price. According to the SEC, on Aug 13, 2015, John C Md Baldwin (director) sold 2,266 shares at $72.00 per share price. On Aug 10, 2015, John B Ziegler (director) sold 2,200 shares at $74.35 per share price, according to the Form-4 filing with the securities and exchange commission.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.